Papers by Meletios Α. Dimopoulos
Page 12 · newest first
- Disease control should be the goal of therapy for WM patientsBlood Advances · 2017
- The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agentsBlood · 2017
- Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaBlood · 2017
- An overview of the role of carfilzomib in the treatment of multiple myelomaExpert Opinion on Pharmacotherapy · 2017
- Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal functionClinical Pharmacology Advances and Applications · 2017
- Gefitinib: an “orphan” drug for non-small cell lung cancerExpert Opinion on Orphan Drugs · 2017
- Mechanisms of bone destruction in multiple myelomaEuropean Journal of Cancer Care · 2017
- Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studiesLeukemia & lymphoma/Leukemia and lymphoma · 2017
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupBlood Cancer Journal · 2017
- Daratumumab combinations: what can we learn?Blood · 2017
- Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional casesLeukemia & lymphoma/Leukemia and lymphoma · 2017
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growthBritish Journal of Haematology · 2017
- Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesEuropean Journal Of Haematology · 2017
- Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.BMC Cancer · 2017
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialBritish Journal of Haematology · 2017
- Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomibBlood Cancer Journal · 2017
- Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefitBlood Cancer Journal · 2017
- Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical EvaluationThe Oncologist · 2017
- Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysisEuropean Journal Of Haematology · 2017
- Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatmentBlood Cancer Journal · 2017
- Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyAmerican Journal of Hematology · 2017
- Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupLeukemia & lymphoma/Leukemia and lymphoma · 2017
- Cardiac and renal complications of carfilzomib in patients with multiple myelomaBlood Advances · 2017
- Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyBritish Journal of Haematology · 2017
- Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyBritish Journal of Haematology · 2017
- Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM ‐8 consensus panelBritish Journal of Haematology · 2017
- Emerging treatment approaches for myeloma-related bone diseaseExpert Review of Hematology · 2017
- Efficacy and safety of elotuzumab for the treatment of multiple myelomaExpert Opinion on Drug Safety · 2017
- Current treatment options and investigational drugs for Waldenstrom’s MacroglobulinemiaExpert Opinion on Investigational Drugs · 2017
- Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential HypertensionInternational Journal of Hypertension · 2017
- Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORLeukemia · 2016
- Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimensLeukemia & lymphoma/Leukemia and lymphoma · 2016
- A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL AmyloidosisBlood · 2016
- Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG StudyBlood · 2016
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)Blood · 2016
- Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of PolluxBlood · 2016
- Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)Blood · 2016
- BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsBlood · 2016
- Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myelomaBlood Cancer Journal · 2016
- Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaHaematologica · 2016
- Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemiaLeukemia & lymphoma/Leukemia and lymphoma · 2016
- High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myelomaBlood Cancer Journal · 2016
- Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeHaematologica · 2016
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2016
- Current treatments for renal failure due to multiple myelomaExpert Opinion on Pharmacotherapy · 2016
- Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcomeHematological Oncology · 2016
- Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple MyelomaRadiology · 2016
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaJournal of Clinical Oncology · 2016
- Carfilzomib for treating myelomaExpert Opinion on Orphan Drugs · 2016
- DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7Blood · 2016